Inhibikase Therapeutics (IKT) Stock Chart & Stock Price History $2.36 -0.06 (-2.48%) (As of 11/14/2024 ET) Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends Inhibikase Therapeutics Stock Price Performance5 Day Performance-17.01%1 Month Performance+50.31%3 Month Performance+83.85%6 Month Performance+57.24%Year-To-Date Performance+88.19%1 Year Performance+154.26% Receive IKT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter Email Address Ad True Gold RepublicCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold. Click here now to get your free 'Protect Your Wealth' Guide. IKT Stock Chart for Thursday, November, 14, 2024 IKT Chart by TradingView Inhibikase Therapeutics Share Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization11/13/2024$2.89$2.42-16.26%$2.87$2.29376,763 shs$18.05 million11/12/2024$2.87$2.89+0.70%$2.89$2.57211,407 shs$21.56 million11/11/2024$2.88$2.87-0.35%$3.20$2.60660,399 shs$21.41 million11/08/2024$2.78$2.88+3.60%$3.69$2.851.57 million shs$21.50 million11/07/2024$2.69$2.78+3.35%$2.79$2.56250,399 shs$20.75 million11/06/2024$2.65$2.69+1.51%$2.75$2.62127,583 shs$20.07 million Get the Latest News and Ratings for IKT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/05/2024$2.61$2.65+1.53%$2.71$2.61100,106 shs$19.77 million11/04/2024$2.64$2.61-1.14%$2.75$2.44165,464 shs$19.47 million11/01/2024$2.53$2.64+4.35%$2.73$2.5485,917 shs$19.69 million10/31/2024$2.77$2.53-8.66%$2.80$2.37346,213 shs$18.88 million10/30/2024$2.64$2.77+4.92%$2.78$2.57191,934 shs$20.68 million10/29/2024$2.74$2.64-3.65%$2.79$2.56193,186 shs$19.69 million10/28/2024$2.42$2.74+13.22%$2.79$2.43528,926 shs$20.44 million10/25/2024$2.52$2.42-3.97%$2.61$2.37288,329 shs$17.46 million10/24/2024$2.43$2.52+3.70%$2.62$2.40664,357 shs$18.18 million10/23/2024$2.11$2.43+15.17%$2.54$2.15470,766 shs$17.54 million10/22/2024$2.22$2.11-4.95%$2.13$1.90173,563 shs$15.23 million10/21/2024$2.13$2.22+4.23%$2.43$2.20197,163 shs$16.02 million10/18/2024$2.35$2.13-9.36%$2.33$2.00273,097 shs$15.37 million10/17/2024$1.94$2.35+21.13%$2.51$1.89643,528 shs$16.96 million10/16/2024$1.71$1.94+13.45%$2.04$1.65444,257 shs$14.00 million10/15/2024$1.59$1.71+7.55%$1.73$1.52259,774 shs$12.34 million10/14/2024$1.47$1.59+8.16%$1.64$1.40340,912 shs$11.47 million10/11/2024$1.30$1.47+13.08%$1.50$1.27679,728 shs$10.97 million10/10/2024$1.26$1.30+3.17%$1.34$1.15789,574 shs$9.38 million10/09/2024$1.19$1.26+5.88%$1.88$1.1519.36 million shs$9.09 million10/08/2024$1.25$1.19-4.80%$1.30$1.1724,258 shs$8.59 million10/07/2024$1.26$1.25-0.79%$1.31$1.2012,961 shs$9.02 million10/04/2024$1.27$1.26-0.79%$1.31$1.266,940 shs$9.09 million10/03/2024$1.28$1.27-0.78%$1.29$1.224,431 shs$9.16 million10/02/2024$1.22$1.28+4.92%$1.30$1.199,244 shs$9.24 million10/01/2024$1.30$1.22-6.15%$1.31$1.2210,901 shs$8.80 million09/30/2024$1.17$1.30+11.11%$1.30$1.1914,573 shs$9.38 million09/27/2024$1.13$1.17+3.54%$1.20$1.139,155 shs$8.73 million09/26/2024$1.15$1.13-1.74%$1.17$1.1316,928 shs$8.43 million09/25/2024$1.15$1.15$1.22$1.1329,822 shs$8.58 million09/24/2024$1.17$1.15-1.71%$1.19$1.1512,468 shs$8.30 million09/23/2024$1.20$1.17-2.50%$1.24$1.1714,294 shs$8.44 million09/20/2024$1.16$1.20+3.45%$1.22$1.1741,405 shs$8.66 million09/19/2024$1.17$1.16-0.85%$1.23$1.1621,733 shs$8.37 millionBlackrock’s Sending THIS Crypto Higher on Purpose (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW09/18/2024$1.16$1.17+0.86%$1.24$1.168,588 shs$8.44 million09/17/2024$1.16$1.16$1.30$1.1515,458 shs$8.37 million09/16/2024$1.18$1.16-1.69%$1.31$1.1535,158 shs$8.37 million09/13/2024$1.20$1.18-1.67%$1.29$1.1817,502 shs$8.80 million09/12/2024$1.32$1.20-9.09%$1.40$1.1733,868 shs$8.66 million09/11/2024$1.34$1.32-1.49%$1.43$1.2735,276 shs$9.53 million09/10/2024$1.38$1.34-2.90%$1.51$1.3155,091 shs$9.67 million09/09/2024$1.34$1.38+2.99%$1.39$1.295,683 shs$10.30 million09/06/2024$1.36$1.38+1.47%$1.39$1.288,030 shs$9.96 million09/05/2024$1.35$1.36+0.74%$1.40$1.341,228 shs$9.81 million09/04/2024$1.34$1.35+0.75%$1.43$1.274,599 shs$10.07 million09/03/2024$1.40$1.34-4.29%$1.41$1.296,799 shs$10.00 million09/02/2024$1.40$1.40$1.40$1.333,000 shs$10.44 million08/30/2024$1.39$1.45+4.58%$1.45$1.333,098 shs$10.46 million08/29/2024$1.39$1.39-0.25%$1.42$1.3410,604 shs$10.01 million08/28/2024$1.40$1.39-0.71%$1.45$1.3126,684 shs$10.03 million08/27/2024$1.45$1.40-3.45%$1.45$1.358,660 shs$10.10 million08/26/2024$1.43$1.45+1.40%$1.56$1.3492,624 shs$10.46 million08/23/2024$1.40$1.43+2.14%$1.46$1.3311,272 shs$10.32 million08/22/2024$1.45$1.40-3.45%$1.48$1.3121,745 shs$10.10 million08/21/2024$1.41$1.45+2.84%$1.45$1.398,270 shs$10.46 million08/20/2024$1.34$1.41+5.22%$1.59$1.29114,892 shs$10.18 million08/19/2024$1.27$1.34+5.51%$1.38$1.1918,035 shs$9.67 million08/16/2024$1.28$1.27-0.78%$1.34$1.207,607 shs$9.16 million08/15/2024$1.30$1.28-1.54%$1.39$1.207,808 shs$9.24 million08/14/2024$1.37$1.30-5.11%$1.38$1.2815,713 shs$9.38 million08/13/2024$1.32$1.37+3.79%$1.41$1.3016,683 shs$9.89 million Related Companies IKNA Stock Price Chart MGX Stock Price Chart JATT Stock Price Chart BLUE Stock Price Chart ZIVO Stock Price Chart QNCX Stock Price Chart AGEN Stock Price Chart DTIL Stock Price Chart OMGA Stock Price Chart ALVR Stock Price Chart Receive IKT Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NYSE:IKT) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Coins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of...Golden Crest | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredElon Musk has put himself in their crosshairsToday, I have another controversial prediction. One which I will take no pleasure in seeing come true. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
